MYCN and neuroblastoma: We have found that MX25-1 exhibits these effects by binding to MYCN 3’UTR and inducing MYCN mRNA degradation, thus providing proof-of-principle that targeting MYCN mRNA is likely an effective and novel therapeutic approach for MYCN-amplified/refractory NB patients.